CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19
Sang Youl Rhee, Jeongwoo Lee, Hyewon Nam, Dae-Sung Kyoung, Dong Wook Shin, Dae Jung Kim
Diabetes Metab J. 2021;45(2):251-259.   Published online March 5, 2021
DOI: https://doi.org/10.4093/dmj.2020.0206

Excel Download

Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19 (Diabetes Metab J 2021;45:251-9)
Diabetes & Metabolism Journal. 2021;45(4):615-616   Crossref logo
Link1 Link2 Link3

Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19 (Diabetes Metab J 2021;45:251-9)
Diabetes & Metabolism Journal. 2021;45(4):619-620   Crossref logo
Link1 Link2 Link3

Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19
Diabetes & Metabolism Journal. 2021;45(2):251-259   Crossref logo
Link1 Link2 Link3

The effects of sitagliptin, a DPP-4 inhibitor, on cognitive functions in elderly diabetic patients with or without Alzheimer’s disease
Diabetes Research and Clinical Practice. 2017;123:192-198   Crossref logo
Link1 Link2

Association Between DPP-4 Inhibitors and COVID-19–Related Outcomes Among Patients With Type 2 Diabetes
Diabetes Care. 2021;44(4):e64-e66   Crossref logo
Link1

Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on m
Diabetes, Obesity and Metabolism. 2017;19(3):394-400   Crossref logo
Link1 Link2

Efficacy and safety of once-weekly GLP-1 RA in patients with type 2 diabetes treated with DPP-4 inhibitor
Diabetes Research and Clinical Practice. 2016;120:S105   Crossref logo
Link1 Link2

Treatment with a DPP-4 inhibitor at time of hospital admission for COVID-19 is not associated with improved clinical outcomes: data from the COVID-PREDICT cohort study in The Netherlands
Journal of Diabetes & Metabolic Disorders. 2021;   Crossref logo
Link1 Link2 Link3

Clinical characteristics and outcomes of COVID-19 patients with prediabetes
Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2021;15(4):102192   Crossref logo
Link1 Link2

Dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in coronavirus disease 2019 (COVID-19) – A systematic review, meta-analysis, and meta-regression
Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2021;15(3):777-782   Crossref logo
Link1 Link2